Nov 26 (Reuters) - AstraZeneca Plc is likely to run
an additional global trial to assess the efficacy of its
COVID-19 vaccine, according to the company's Chief Executive
Pascal Soriot, Bloomberg News reported on Thursday.
Instead of adding the trial arm to an ongoing U.S. process,
a new trial would be run to evaluate a lower dosage that
performed better than a full amount in AstraZeneca's studies,
the report said https://www.bloomberg.com/news/articles/2020-11-26/astra-likely-to-run-fresh-global-covid-vaccine-trial-ceo-says?sref=2h1zKciy.
AstraZeneca is facing tricky questions about its success
rate that some experts say could hinder its chances of getting
speedy U.S. and EU regulatory approval.
Several scientists have raised doubts about the robustness
of results showing the shot was 90% effective in a sub-group of
trial participants who, by error initially, received a half dose
followed by a full dose.
(Reporting by Sabahatjahan Contractor in Bengaluru; Editing by
Jan Harvey)